Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.

BofA analyst Travis Steed raised the firm’s price target on Becton Dickinson (BDX) to $269 from $265 and keeps a Buy rating ...

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest ...

(This Feb. 5 story has been refiled to correct the name of the unit to biosciences and diagnostic solutions, from life sciences, in the headline and paragraphs 1 and 4) (Reuters) - Becton Dickinson ...

Bruker Corporation (Nasdaq: BRKR) today announced it will report fourth quarter and fiscal year 2024 financial results before ...

SG Americas Securities LLC cut its stake in Fulgent Genetics, Inc. (NASDAQ:FLGT – Free Report) by 28.3% in the fourth quarter, Holdings Channel.com reports. The fund owned 12,518 shares of the company ...

Q1 2025 Management View Tom Polen emphasized several key updates, including the planned separation of BD’s Biosciences and Diagnostic Solutions businesses, which aims to create two strategically ...

Becton Dickinson & Co. said it’s planning to separate part of its life sciences segment in a move aimed at raising the medical technology company’s stock.

The board of directors of Franklin Lakes-based, global medical technology company BD, has unanimously authorized BD management ...

Healthcare is undergoing a seismic transformation. The old paradigm of brick-and-mortar hospitals is giving way to a new ...

Consultation launches on the biggest shake-up of NICE's HealthTech programme to date. More innovative healthcare technologies could soon be adopted by the NHS under reforms proposed today by NICE.

From chatbots supporting patients to AI diagnostic tools, artificial intelligence is reshaping healthcare delivery, as evidenced at the IMAGINE AI event.